Tadayoni R, et al. – This study was performed to assess the long–term (24–month) effectiveness and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser utilizing an individualized visual acuity (VA) stabilization criteria in patients with visual impairment because of macular edema secondary to branch retinal vein occlusion (BRVO). The BRIGHTER study results affirmed the long–term effectiveness and safety profile of PRN dosing driven by individualized VA stabilization criteria utilizing ranibizumab 0.5 mg in patients with BRVO. The addition of laser did not lead to better functional outcomes or lower treatment need. The safety results were consistent with the well–established safety profile of ranibizumab.